Profile of drug interactions in hospitalized children by Martinbiancho, Jacqueline Kohut et al.
Martinbiancho J, Zuckermann J, Dos Santos L, Silva MM. Profile of drug interactions in hospitalized children. 




Introduction: The expected therapeutic response 
may be affected by the presence of drug 
interactions. With the high number of reports on 
new drug interactions, it has been difficult for health 
professionals to keep constantly updated. For this 
reason, computer systems have helped identify 
such interactions. 
Objectives: To verify the rate and profile of drug 
interactions in medical prescriptions to hospitalized 
pediatric patients. 
Methods: A descriptive study investigated 
prescriptions to hospitalized pediatric patients. The 
study included patients between 0 and 12 years old, 
containing 4 or more drugs in their prescriptions. 
The analysis of interaction and incompatibility 
possibilities in prescribed drugs used Micromedex / 
Drug-Reax® program. 
Results: From 2005 to 2006, 3,170 patients were 
investigated, and 11,181 prescriptions were 
analyzed, a mean value of 3.5 prescriptions/patient. 
In total, 6,857 drug interactions were found, which 
corresponds to 1.9 interaction/prescription. Among 
them, relevance to ampicillin and gentamicin, found 
in 220 (3.2%) prescriptions. In total, 2,411 drug 
incompatibilities in via y were found, a mean value 
of 0.5/prescription, with emphasis on vancomycin 
and cefepime, found in 243 (10.0%) prescriptions. 
Conclusion: The presence of drug interactions is a 
permanent risk in hospitals. This way, the utilization 
of computer programs, pharmacotherapy monitoring 
of patients and the pharmacist presence in the 
multidisciplinary team are some manners of 
contributing to hospitalized patients’ treatment. 
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RESUMEN 
Introducción: La respuesta terapéutica esperada 
puede modificarse por la presencia de interacciones 
medicamentosas. Con el elevado número de 
comunicaciones de nuevas interacciones 
medicamentosas, ha sido difícil para los 
profesionales de la salud mantenerse 
constantemente actualizados. Por este motivo, los 
ordenadores han ayudado a identificar estas 
interacciones. 
Objetivos: Verificar la tasa y el perfil de las 
interacciones medicamentosas en las prescripciones 
médicas a pacientes pediátricos hospitalizados. 
Métodos: Un estudio descriptivo investigó las 
prescripciones a pacientes pediátricos 
hospitalizados. El estudio incluyó pacientes entre 0 
y 12 años, que tenían 4 o más medicamentos en sus 
prescripciones. El análisis de las interacciones y las 
incompatibilidades posibles en los medicamentos 
prescritos utilizó el programa Micromedex / Drug-
Reax®. 
Resultados: De 2005 a 2006, se investigó a 3.170 
pacientes y se analizaron 11.181 prescripciones con 
una media de 3,5 recetas/paciente. En total se 
encontraron 6.857 interacciones medicamentosas, 
que corresponden a 1,9 interacciones/prescripción. 
Entre ellas, se encontró relación a ampicilina y 
gentamicina en 220 (3,2%). En total, se encontraron 
2.411 incompatibilidades de vía, con una media de 
0,5 por prescripción, con énfasis en vancomicina y 
cefepime, encontradas en 243 (10,0%). 
Conclusión: La presencia de interacciones 
medicamentosas es un riesgo permanente en 
hospitales. Así que, la utilización de un programa 
informático, el seguimiento farmacoterapéutico de 
los  pacientes y la presencia de un farmacéutico en 
el equipo multidisciplinario son algunas de las 
maneras de mejorar el tratamiento de los pacientes 
hospitalizados. 
  
Palabras clave: Interacciones medicamentosas. 






The concomitant and extended utilization of two or 
more drugs in a treatment, either due to the 
patient’s pathological condition or the need for 
action or effect complementation, is known as 
polypharmacy. The isolated utilization of such drugs 
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may bring numerous benefits, but the expected 
therapeutic response may be affected by the 
presence of drug interactions. The main causes of 
hospital admissions and mortalities are related to 
drug interactions and their corresponding adverse 
effects.1,2 
Drug interactions refer to the interference of a drug 
in the action of another drug or the interference of 
food or nutrient in the action of drugs.2-4 It is 
estimated that interactions occur in 3 to 5% of 
patients receiving few drugs, and when 10 to 20 
drugs are used, this rate reaches 20%.1,5 
They can be divided into pharmaceutical, 
pharmacokinetic or pharmacodynamic3,5 
interactions. Pharmaceutical interactions, known as 
drug incompatibilities, occur before the drug 
administration in the body, when two or more of 
them are mixed in the same serum accessory, 
syringe or other recipient, and are evidenced by 
organoleptic alterations, reduced or interrupted 
activity of one or both drugs or formation of a new 
compound. Pharmacokinetic interactions occur 
during drug absorption, distribution, 
biotransformation and excretion processes, 
resulting in increased or reduced plasmatic 
concentration and consequently alteration to the 
pharmacological effect. Pharmacodynamic 
interactions are responsible for synergism and 
antagonism effects among drugs, and occur at their 
action sites.3-5 
Drug interactions may produce beneficial or 
desirable, or undesirable or harmful effects.4 The 
beneficial effects are those whose purpose is to 
treat concomitant diseases, enhancing the 
effectiveness, reducing adverse effects and allowing 
to reduce the dose, while the undesirable effects 
may reduce the drug effectiveness, and may 
produce adverse and even toxic effects in the body, 
besides increased treatment cost. The undesirable 
interactions may result in different impacts on the 
patient. They are subdivided into severe 
interactions, which may produce a risk to life or 
permanent damages, moderate interactions, which 
require additional treatment, and mild interactions, 
which do not affect significantly the therapy effect.6 
Pediatric patients require special attention from 
health professionals in terms of drug interactions, as 
they react to drugs differently from adults. The body 
parts that are responsible for the excretion and 
elimination processes are not fully developed until 1 
year of age, resulting in extended half-life of 
metabolized drugs and reduced excretion, which 
may result in toxicity problems.4,5,7 
Regarding the treatment of a drug interaction 
occurrence that may be harmful to the patient, the 
health professional should: avoid complex 
therapeutic systems, adopt alternative measures, 
provide instructions on the correct interval between 
drug administrations, determine the probability of 
important interaction occurrences and monitor the 
patient.5,7 
With the high number of reports on new drug 
interactions, it has been difficult for health 
professionals to keep constantly updated. Today, 
computer systems are used to verify the risk of 
potential drug interactions, thus preventing the 
utilization of drugs that cause important and harmful 
interactions and reducing the patient's exposure to 
them. For this reason, the purpose of this study was 
to verify the rate and profile of drug interactions in 




A descriptive study was performed from January of 
2005 to December of 2006 to verify the rate of drug 
interactions and its clinical meaning in medical 
prescriptions to pediatric patients during the 
hospitalization period at a Brazilian teaching 
hospital, which has 750 beds, 71 of them dedicated 
to pediatric patients. 
The study included hospitalized patients between 0 
and 12 years old, containing 4 or more drugs in their 
medical prescriptions, excluding the topical drugs 
(ointments, creams, ear drops, eye drops). The 
study excluded patients hospitalized in emergency 
areas, intensive care unit and oncology unit. Mean 
length-of-stay of patients hospitalized in pediatric 
unit is approximately 5 days. 
The selected patients were investigated during the 
hospitalization period. Their electronic prescriptions 
were analyzed 3 times a week by a pharmacist and 
2 scholarship holders in Pharmaceutics. The 
analysis of interaction and incompatibility 
possibilities in via y among prescribed drugs was 
performed through Micromedex/Drug-Reax® 
program. Based on the interactions found in the 
prescriptions, an analysis was performed on their 
relevance to the patient’s current situation, and after 
that, the medical teams were informed using the 
standard service form of the hospital’s 
pharmaceutical area. 
For the purposes of this study, the drug interactions 
found and informed to the medical teams were 
classified in terms of interaction severity, effect start 
and literature documentation. 
The interaction effect start classification is important 
for defining the treatment of interaction 
consequences to the patient. The consequences 
can have a ‘fast’ start, when the effects are evident 
within 24 hours and a prompt intervention is 
required, or a ‘delayed’ start, when the effects can 
take days or weeks to be evident. However, they 
may not be specified in the literature, due to 
insufficient studies.1,3,7 
Regarding the interaction effect severity, the 
interactions can be classified as severe, when they 
can affect the clinical evolution or promote 
permanent damages to the patient, requiring 
intervention(s) to minimize or prevent serious 
effects; ‘moderate’, when the effects can produce 
aggravations or clinical alterations, requiring 
changes in the therapy, and ‘mild’, when they are 
not significant to affect the patient's therapy, as they 
result in mild or inconvenient effects, and do not 
require a greater therapy intervention.1,3,7 
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The biomedical-based literature documentation 
shows the possibility of drug interaction occurrences 
and the alterations they may cause to the patients’ 
clinical responses. They are classified as ‘excellent 
documentation’, when the studies have clearly 
established the interaction existence; ‘well-
documented’, when they strongly suggest the 
interaction existence, but there are not many 
controlled studies supporting it; ‘satisfactory 
documentation’, when it is insufficient, but presents 
pharmacological considerations on the interaction 
existence; ‘insufficient documentation’, when there 
are few studies and the reported cases are limited; 
and ‘improbable documentation’, when it is 
insufficient and without pharmacological base.3,4 
The study was approved by the Research Ethics 
Commission and presents a Commitment Term for 
data utilization exclusively for scientific publication 
purposes.
RESULTS  
From 2005 to 2006, 3,170 patients were 
investigated and 11,181 prescriptions were 
analyzed, mean value of 3.5 prescriptions/patient. 
The mean quantity of items per prescription was 10. 
These prescriptions presented 6857 drug 
interactions, being 1.9 interaction/prescription and 
approximately 7 interactions/patient. Table 1 shows 
the most frequent drug interactions in the 
prescriptions. Among them, ampicillin and 
gentamicin were found in 220 (3.2%) prescriptions, 
diazepam and chloral hydrate in 215 (3.1%) and 
valproic acid and phenobarbital in 214 (3.1%) 
prescriptions. 
 
Table 1 - Frequency of drug interactions found in medical prescriptions 
Drug interactions n (%) Effect start Severity level Documentation 
Ampicillin + Gentamicin 220 (3.2%) Fast Mild Good 
Diazepam + Chloral Hydrate 
Valproic Acid + Phenobarbital 
Diazepam + Phenobarbital 

















Phenytoin + Acetaminophen 161 (2.3%) Delayed Moderate Good 
Dipyrone + Furosemide 140 (2.0%) Delayed Moderate Not informed 
Carbamazepine + Acetaminophen 138 (2.0%) Delayed Moderate Good 
Phenobarbital + Prednisolone 127 (1.9%) Delayed Moderate Insufficient 
Diazepam + Phenytoin 111 (1.6%) Delayed Moderate Good 
Total 6857 (100%)    
 
In total, 1,201 (5.6%) drug interactions were notified 
to medical teams, being 204 (17%) of severe level, 
672 (56%) of moderate level and 325 (27%) of mild 
level. 
Regarding drug incompatibilities in y-site, or 
pharmaceutical interactions, 2,411 incompatibilities 
were found, a mean value of 0.5/prescription. Table 
2 shows the most frequent incompatibilities found in 
the prescriptions. Among them, incompatibilities 
between vancomycin and cefepime in 243 (10.0%) 
prescriptions, ampicillin and gentamicin in 216 
(9.0%) and cefepime and metoclopramide in 175 
(7.2%) prescriptions were more relevant. 
 
DISCUSSION 
This study utilized a computer system to verify the 
possibilities of drug interactions in medical 
prescriptions to pediatric patients and warned the 
medical teams, by means of pharmaceutical 
intervention through a differentiated form in the 
folders of patients exposed to such interactions.8-10 
Although the number of clinically relevant drug 
interactions is considered as low, many hospital 
admissions are linked with effects caused by the 
interactions of utilized drugs. 
The computer systems used to verify the 
possibilities of drug interactions are well described 
in the literature as a way to help health 
professionals prevent severe-level interactions and 
adverse effects with potential risks.8,10,11
 
Table 2 - Frequency of drug incompatibilities found in 
medical prescriptions 
Drug incompatibilities n  % 
Cefepime + Vancomycin 243 10.1 
Ampicillin + Gentamicin 216 9.0 
Cefepime + Metoclopramide 175 7.2 
Ampicillin + Metoclopramide 121 5.0 
Furosemide + Metoclopramide 91 3.8 
Potassium Chloride + Diazepam 89 3.7 
Amikacin + Ceftazidime 47 1.9 
Cefepime + Diazepam 47 1.9 
Piperacillin/Tazobactam + 
Vancomycin 44 1.8 
Gentamicin + Oxacillin 44 1.8 
Others 1294 53.7 
Total 2411 100 
The probability of drug interaction occurrences 
increases in patients that receive 10 or more drugs. 
In this study, the obtained drug interaction rate was 
61.3%, with mean quantity of 10 items/analyzed 
prescription. 
According to the analysis, due to the number of 
prescribed drugs, most patients presented one or 
more potential drug interactions, with mean value of 
1.9/prescription, which may reach higher values.1,10 
Regarding the severity of interactions, 17% of all 
detected interactions were considered at severe 
level, which could consequently promote or cause 
permanent damages to patients; 56% of the 
interactions were considered as moderate, 
indicating that the treatment could have an 
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impacted or different therapeutic response from the 
expected reaction, due to a drug intervention in the 
action of another drug. 
Concerning the drug interactions found at higher 
frequency in the prescriptions, the 
pharmacodynamic interactions between 
aminoglycoside and beta-lactam antibiotics are well 
described in terms of their synergism effects. 
Regarding the concomitant administration of such 
drugs, fast and mild effects are observed in the 
patients, which may cause aminoglycoside 
antibiotics to lose their effectiveness through a 
chemical inactivation caused by beta-lactam 
antibiotics.5 For this reason, it is suggested to 
monitor the serum effects of aminoglycoside 
antibiotics in patients, and the concomitant 
administration of aminoglycoside and beta-lactam 
antibiotics through intravenous system should be 
avoided, allowing intervals of 1-2 hours between 
them7,10; also because of the frequent drug 
incompatibilities of aminoglycoside antibiotics with 
other drugs. 
Chloral hydrate, a non-diazepam sedative drug, and 
benzodiazepam drugs may produce effects of 
respiratory depression, as the effect start is not 
specified in the literature and because it is a severe-
level interaction, which requires the respiratory 
depression monitoring when such drugs are 
combined. 
The concomitant utilization of valproic acid and 
phenobarbital in 30-50% of the patients results in a 
well-documented interaction in literature considered 
at moderate level and delayed effect start. The 
interaction result, an enzymatic induction through 
Cytochrome P450, generates elevated serum levels 
of phenobarbital and reduced effects of valproic 
acid, through the drug metabolism induction.5,12 
Dose adjustment is recommended in order to avoid 
toxicity.13 
Incompatibilities between 2 or more drugs indicate 
that they should be administered separately in order 
to avoid drug effectiveness loss. Vancomycin and 
cefepime are antibiotics that depend on their 
concentration to ensure a safe administration. The 
administration of vancomycin at 5-10 mg/mL 
concentration with 20 mg/mL of cefepime is 
physically incompatible in via y, and it may produce 
disturbances right after the mixture is done and the 
development of precipitates within a 4-hour period 
at ambient temperature.14 
Cefepime and metochlopramide are physically 
incompatible, and they may result in disturbances 
right after they are mixed in via y or concomitantly. 
 
CONCLUSIONS 
The presence of drug interactions is a permanent 
risk in hospitals and the utilization of computer 
programs has become the most effective way to 
identify and treat them. Then, we can conclude that 
continued education, computer system for 
prescriptions, pharmacotherapy monitoring of 
patients and the pharmacist participation in the 
multidisciplinary team are some manners of 
improving the treatment to hospitalized patients. 
After the intervention, the drug interactions found in 
the prescriptions were analyzed every time 
administration by nurses and pharmacists, allowing 
intervals between them to minimize the effects. 
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Stockley's Drug Interactions edited by Karen Baxter, remains the world's most comprehensive and 
authoritative reference book on drug interactions. 
 
 Contains detailed yet concise monographs 
 Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, 
foods, drinks, pesticides and drugs of abuse 
 Based on published sources and fully referenced 
 Provides comprehensive details of the clinical evidence for the interactions under 
discussion, an assessment of their clinical importance and gives clear guidance on how to 
manage the interaction in practice 
 Covers over 17,000 indexed interaction pairs 
 Contains over 3,100 monographs 
 
The eighth edition now contains an additional 300 new monographs and all existing entries 
thoroughly reviewed and revalidated.  Herbal medicine coverage has been extended as well as 
coverage of dietary supplements, foods and fruit juices.  Review monographs have been added to 
aid understanding of the mechanisms behind the interactions. 
 
Stockley's Drug Interactions provides the busy healthcare professional with quick and easy access 
to clinically relevant, evaluated and evidence-based information on drug interactions. 
 
The new edition of Stockley's Drug Interactions can now be purchased at www.pharmpress.com 
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